Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. by Harvey, Orlanda et al.
RESEARCH ARTICLE Open Access
Support for people who use Anabolic
Androgenic Steroids: A Systematic Scoping
Review into what they want and what they
access
Orlanda Harvey1* , Steve Keen1, Margarete Parrish1 and Edwin van Teijlingen2
Abstract
Background: Since there is a paucity of research on support for people using Anabolic Androgenic Steroids (AAS),
we aimed to identify and synthesise the available evidence in this field. Gaining an understanding of the support
both accessed and wanted by recreational AAS users will be of use to professionals who provide services to intravenous
substance users and also to those working in the fields of public health and social care, with the aim to increase
engagement of those using AAS.
Methods: A systematic scoping review of the literature to explore and identify the nature and scope of information and
support both accessed and wanted by non-prescribed AAS users. Any support services or information designed to help
people who use AAS were considered.
Results: We identified 23 papers and one report for review, which indicated that AAS users access a range of sources of
information on: how to inject, substance effectiveness, dosages and side effects, suggesting this is the type of information
users want. AAS users sought support from a range of sources including medical professionals, needle and syringe
programmes, friends, dealers, and via the internet, suggesting that, different sources were used dependent on the
information or support sought.
Discussion: AAS users tended to prefer peer advice and support over that of professionals, and access information online
via specialist forums, reflecting the stigma that is experienced by AAS users. These tendencies can act as barriers to
accessing services provided by professionals.
Conclusions: Support needs to be specific and targeted towards AAS users. Sensitivity to their perceptions of their drug-
use and the associated stigma of being classified in the same sub-set as other illicit drug users is relevant to facilitating
successful engagement.
Keywords: Androgenic anabolic steroids (AAS), Image and performance enhancing drugs (IPED), Support, Harm
minimisation, Advice, Information, Needle and syringe Programmes (NSPs)
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Background
In the UK, just under 54,000 16–59 year-olds reported
having used Anabolic Androgenic Steroids (AAS) in 2015/
2016 [1]. Although representing only a small minority of
all substance users, this is probably underreported due to
the illegality of supply and the use of self-reported data. A
simultaneous increase in the use of needle and syringe
programmes (NSPs) by people using Image and Perform-
ance Enhancing Drugs (IPED) (including AAS) has also
been noted [2]. NSPs provide harm minimisation services
to people who inject substances, which includes handing
out injecting paraphernalia, offering advice on safe inject-
ing and harm minimisation and sometimes screening for
Blood Borne Viruses (BBVs) [3]. Since the late 1980s NSP
support has become an established service for AAS users
[4], in one study of 500 users [5] 99.2% reported using in-
jectable AAS or a combination of injectable and oral sub-
stances and a recent UK survey of 684 AAS users, 85% of
users injected IPED, and steroids were the most com-
monly used IPED [6].
AAS use is linked with negative physical health effects,
such as testicular atrophy, liver toxicity, dermal scarring,
cognitive problems, gynaecomastia, muscle damage, myo-
cardial injuries, infertility [7], and BBVs [8]. AAS users are
at greater risk than non-users of psychological risks such
as: mania, delusions, aggressive behaviours, depression,
suicide and anxiety [9–14]. Pilot studies have shown that
lifetime AAS use may impact on some cognitive processes
and the structural features of the brain [15–17].
Further risks include harm from using AAS in combin-
ation with illicit substances [18], self-medication [19] and
becoming AAS dependent [20]. Importantly, not all AAS
users will experience these. Reasons for starting use vary,
the most prominent being to gain muscle/strength [21,
22] and historically this has been associated with sport.
However, recently a wider range of motivations has been
identified including improved appearance, aggression, per-
sonal security, psychological well-being (including boost-
ing self-esteem or confidence) or satisfaction, sexual
attraction, overcoming depression, curiosity, influence of
family, peers and media [23]. People who use substances
are the experts in their own use [24], therefore, given the
wide range of risks, a variety of motivations (many not
mutually exclusive) and the potential for people to be-
come dependent it is important to understand what sup-
port people who use AAS wish to receive. Getting their
perspectives on ideal support may lead to more effective
engagement with services. Additionally, people working
with substance users need knowledge of the types of sup-
port available, to make changes relevant to their needs
and to reduce the risk of harm to self and others [25].
Consequently, this systematic scoping review explores
the nature and scope of the information and support
accessed and wanted, by investigating two questions:
 What support and information do people using non-
prescriptive AAS recreationally access?
 What support and information do these recreational
AAS users say they want?
Methods
Scoping reviews can be helpful in providing one source
of information for professionals to develop Practice
Guidance [26]. A scoping review follows a systematic
process but allows for flexibility, incorporating changes
as part of the iterative process [27], and allows for the
inclusion of grey literature. To ensure the process was
transparent, robust and replicable, the authors followed
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [28]. Our
protocol is registered in PROSPERO [29].
Search strategy
The wide variation of terms to describe AAS means that
searching the literature is fraught with difficulty and
could lead to key studies being left out, as the term
‘IPED’ is often used when covering a wider variety of
substances than just steroids such as Human Growth
Hormone [30]. Variations on the acronyms included:
PIED, PES, PED, APED, NMASS (non-medical Anabolic
Androgenic Steroid), and terms such as ‘doping’, ‘testos-
terone boosters’, ‘prohormones’, ‘ergogenic aids’ ‘designer
steroids’ and brand names. The first author tested key
words and word groupings, drawn from recent UK Pub-
lic Health literature.
In June 2018 a search was carried out in EBSCO
(Table 1), searching 141 databases. Papers were found in
52 databases (see Additional file 1). Some databases
proved irrelevant, but it was useful to take a multi-
disciplinary approach as it was difficult to predict where
the most pertinent studies might come up. Separate
searches on SCOPUS, Google Scholar and reference lists
of included articles were also undertaken, as electronic
databases may not throw up all available literature [31].
Inclusion and exclusion criteria (Table 2) were applied
initially through a title, abstract and full paper screening.
Publications were limited to those in English (due to
lack of resources for translation), without geographical
restrictions. Irrespective of the study design, articles that
met inclusion criteria were reviewed, i.e. populations
such as recreational users and non-competitive AAS-
using bodybuilders were eligible; there were no age or
gender restrictions. The first author screened and
reviewed all articles. To validate the search strategy the
second author reviewed 10% of articles screened out by
title and 20% screened out by abstract. The second, third
and fourth authors checked 10% each of articles in the
full review.
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Literature search
Our search found several papers relating to question 1,
but few relating to question 2, therefore the search strat-
egy was revised for question 2. Scoping reviews do not
necessarily have to rate the quality of the papers [27],
however the authors concluded that due to the complex-
ity of identifying participants, such a quality review was
of value. Therefore, for question 1, only peer-reviewed
documents were included to ensure a level of quality,
and this proved fruitful when considering support
accessed. However, for question 2, only nine papers gave
limited information on support wanted, therefore the au-
thors searched the references of the included articles for
grey literature (non-peer reviewed) that might include
qualitative data on ‘ideal support’. One report that spe-
cifically sought information relating to ideal support
wanted was identified [33]. Acknowledging this report
was not peer reviewed, the authors felt the information
contained was of value and relevant to the second ques-
tion. Figure 1 outlines the search strategy.
Data extraction and analysis
Information regarding support and advice, population,
substance use, study aims, recruitment methods, meth-
odology and demographics was extracted by the first au-
thor and 30% of data extraction forms were crossed
checked by co-authors. Reviewer agreement on inclusion
and exclusion criteria was 100%. Both qualitative and
quantitative data were included. Due to the different
types of articles, three quality assessment tools were
used: The CASP Checklist [35] for qualitative articles
(Table 3).
For the quantitative studies the Quantitative Review
Methodology tool by Davids and Roman [46] was
adapted. To assess the quality of the grey literature, the
quantitative and qualitative elements were individually
Table 1 Systematic review search strategy - search terms
Search algorithms
anabolic androgenic OR designer N3 steroid* OR recreat* steroid* OR anabolic steroid* OR anabolic drug* OR Synthe* testosterone OR
“Synthe* testosterone” OR “non prescript*” steroid* OR non-prescript* steroid* OR “non-medic*” steroid* OR “non prescri*” N2 steroid*
OR non-prescri* N2 steroid* OR “non medic*” N2 steroid* OR non-medic* N2 steroid* OR performance N3 enhanc* drug* or image N3
enhanc* drug* or appearance N3 enhanc* drug* or muscle N3 enhanc* drug* OR muscle N3 develop* drug* or performance N3
develop*drug* OR doping N3 steroid*
NOT animal* OR mice OR rats OR “guinea pig*” OR spectrometry OR bovine
AND Support or advice or help or aid or barrier* or information or guidance or intervention* or “needle exchange* or program*”
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Studies including populations such as recreational AAS users,
non-competitive AAS-using bodybuilders and weightlifters and,
AAS users accessing drug services.
Studies involving participants who compete professionally and any study
that focuses on competitive sports/athletes or high school athletes
Peer-Reviewed Papers^ Studies on wider drugs prevention interventions or strategies
Qualitative and Quantitative data Studies that made passing references to participants seeking information
but did not clarify the type of support or information including studies
which showed an increase in people using NSPs but did
not share exactly what they were using them for
Studies where participants were asked about where they access
support, advice and information to help them manage their
substance use and that identified the types of support and
information they were seeking.
Specific medical interventions i.e. efficacy of treatments for side effects
Studies that included data collected on any support (information,
advice, service or intervention) designed to support people who
use IPED
Studies that focussed on prevention of AAS use and efficacy of such
interventions
Studies that referenced participants attitudes to who they trusted around
information but did not specifically state the types of information or support
Studies that were solely based on recommendations of professionals as to
what support and information was needed but where the voice of the AAS
user was absent
Articles not in English
Studies before the predominance of the internet as a source of information
i.e. pre 2001. In 2001 the number of internet users went over 500 million
worldwide [32]
^ due to the limited number of articles found to answer the second question, inclusion criteria were modified to include relevant grey literature from references
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assessed using the aforementioned assessment tools, then
the Mixed Methods Appraisal Tool [47] was used, to as-
sign an overall quality score. Studies scoring ** or above
(*** 67–100% & **34–66% score) were included (Table 4)
and no studies were excluded on the basis of quality.
There have been several challenges when identifying
and reviewing the literature. The number of different
terms that cover AAS is inconsistent (Table 1). Identifying
purely recreational users was difficult due to a lack of
granularity when studies consider AAS/IPED use e.g.
terms such as bodybuilder, weightlifter and athlete were
utilised both for competitive and recreational use. Not all
studies identified whether participants used solely AAS or
in combination with other IPED. Due to the heteroge-
neous nature of the data this review takes a narrative ap-
proach. Moreover, unless clearly stated as AAS use within
the study, the generic term IPED will be used.
Analysis was mixed method as scoping reviews can incorp-
orate numerical summaries alongside thematic analysis of
qualitative data [56]. Initially tabulations were used for the
quantitative data, which led to the identification of specific
categories such as BBV checks and acquisition of injecting
equipment. Thematic analysis was conducted in an inductive
way, each article was read to identify types of information and
support and then categorised into type 1 (information or sup-
port accessed) or type 2 (information or support wanted).
The research team met frequently to discuss the emerging
themes, which led to the identification of three overarching
themes: harm minimisation, research and information and
support for health concerns. Then sub categories were identi-
fied based on the type of information or support. It was chal-
lenging to identify the type of information participants were
searching for and in these instances the authors coded this
data as ‘seeking of general information on IPED use’.
Results
For question 1, twenty-three papers: eleven quantitative
articles (nine studies) and twelve qualitative articles
(nine studies) were included as for several papers the
same data set was used to explore different questions re-
lated to the use of AAS (Fig. 1). For question 2, nine
studies were included and one report.
Fig. 1 PRISMA 2009 Flow Diagram [34]
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Sample sizes for IPED-using participants ranged from
six to 1955. All studies incorporated data on information
or support accessed and the majority were self-reported.
Ten studies featured only male AAS-using participants. In
the seven studies where gender was recorded there were
only twenty women, and one study of 253 men, and 59
women, did not report the gender split after participants
who reported no adverse effects were excluded, leaving a
mixed-gender sample of 195. One study included women
but only as non AAS-users [49]. Two studies: one on an
anti-doping hotline [50] and another on online forum
posts [44] had incomplete demographic data and one did
not record discreet visits of NSP services [51].
Information and support sought
IPED users sought different types of information and
support from a range of potentially overlapping sources:
NSPs, pharmacies, doctors, sexual health clinics, other
medical professionals, peers, coaches/trainers, friends,
dealers, family, the internet, specialist online fora, experi-
enced users, steroid guides in gyms, underground books,
online videos and addiction clinics (Table 5).
Harm minimisation and advice
Ten studies evidenced IPED users obtaining injecting
equipment from NSPs. However, five studies recruited from
harm reduction services [19, 43, 51, 53, 54] and one had
predominantly NSP clients [3, 22, 42]. This could explain
the prevalence of NSPs as places to access injecting equip-
ment. Hanley Santos and Coomber [43] noted that some
reported no difficulties using NSPs, found services easy to
access, anonymous, discreet and they valued the advice.
However, they also reported users collecting supplies on be-
half of friends who were afraid of being recognised. Else-
where 44% of IPED users obtained needles on behalf of
others and 27% acquired needles from friends [54]. In one
study of 1716 internet forum posts, it was evident, although
not explicitly stated, that NSPs and anti-aging clinics were
Table 3 Summary of papers included: Qualitative studies
First author, year
& reference
Country Participants defined, (age
range/mean), gender
No. of participants Type of data # Sources potential bias &
limitations
Quality
review~
Maycock (2005)
[36]
Australia Used or had used AAS and
dealers, men
42 AAS users, 22
dealers
#Qualitative: Participant
observation (147), interviews
include longitudinal (10 over
3 years)
Purposive sampling **
Grogan (2006) [37] UK Use(d) AAS, 5 men, 6
women
11 #Qualitative: interviews Small sample ***
Skårberg (2008)
[38]
Sweden Addiction clinic patients
who use(d) AAS, 4 men, 2
women
6 Qualitative interviews: case-
study
Sought help for AAS use.
Small sample
**
Kimergård (2014)
[39]
England
& Wales
AAS users and harm
reduction service providers
(mean = 34), men
24 Qualitative: semi-structured
interviews
Bias towards those
showing positive health
behaviours
***
Kimergård (2014)
[3]
England
& Wales
Used or had used AAS,
men
24 #Qualitative: semi-structured
interviews
same study as above ***
Kimergård (2015)
[22]
England
& Wales
AAS users, men 24 #Qualitative: semi-structured
interviews
same study as above ***
Van Hout (2015)
[40]
UK IPED users, men 20 #Qualitative: in-depth
interviews
Privileged access
recruitment^
***
Dunn (2016) [41] Australia Used or had used AAS, 19
men and 2 women
21 #Qualitative: semi-structured
interviews
Voucher for taking part;
one region (non-rural),
length of interviews
varied
***
Griffiths (2016)
[42]
Australia Used or had used AAS, 24
men 2 women
26 #Qualitative: semi-structured
interviews
– same study as above ***
Hanley Santos
(2017) [43]
UK AAS users, 21 men 1
woman
22 Qualitative: semi-structured
interviews
Bias towards those
showing positive health
behaviours - £10 given
***
Tighe (2017) [44] Australia Specialist forum users,
(none), unknown
450 unique
avatars
Qualitative: threads from 3
Online forums: 134 threads:
1716 posts
Australian sites yet
people from other
countries on forums
***
Greenway (2018)
[45]
UK AAS Users, male 8 Qualitative: interviews Sample bias, one NSP ***
~ Quality Review: Qualitative studies: CASP Checklist for Qualitative Research [34] was used: *** 90% boxes checked as yes, evident, ** if equal to or greater than
70% checked. ^The authors acknowledged that one interviewer had privileged access, here that is likely to be an insider within this sub-community [49] #where
practicable data analysed from studies which included dealers or professional services providers, only findings from AAS users have been included
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being used since experienced IPED users advised inexperi-
enced users to access such services [44].
Table 5 shows that some IPED users did access HiV tests
and/or vaccinations for BBVs; although take up was not
high. Those who had discussed their AAS use with a doctor
were more likely to have undertaken a test for Hep B or C,
or HiV [8] and one study found that people screened for
Hep B or C and HiV were more likely than those who did
not to rate their overall experience with the doctor as good
[56]. AAS users also sought advice on safer injecting.
Research and information seeking
As Table 6 highlights IPED users’ general information
about IPED use was sought from a range of sources par-
ticularly internet sites and subject specific fora. Only
four studies evidenced AAS users seeking information
from medical professionals [36, 49, 52, 57]. Rowe et al.
[8] found that NSP staff were perceived as the most reli-
able source of information relating to IPED followed by
nurses and doctors, however others found doctors’
knowledge limited [36, 38, 58]. For more specific infor-
mation around cycling and stacking (i.e. what combin-
ation of substances are used over what length of time),
dealers, fellow users and online fora were utilised. May-
cock and Howat [36] found that experienced users and
dealers were seen as a credible source of information.
This is not without risk as substances may affect individ-
uals differently, dependent on physiological make-up
and patterns of use. One study found that over 60% of
AAS users reported getting incorrect information about
Table 4 Summary of papers included: Quantitative and mixed methods studies
First author, year
& reference
Country Participants defined, (age
range/mean), gender
No. of participants Type of data # Sources, potential
bias & limitations
Quality
review~
Parkinson (2006)
[5]
USA AAS users, 494 men 6
women
500 Quantitative: web-based
questionnaire
Web-based, self-
selected, self-
report
**
Cohen (2007) [48] US AAS users (Non-medical),
men
1955 Quantitative: web-based survey Online population ***
Larance (2008)
[49]
Australia IPED users, men 60 #Quantitative: cross -sectional
structured Interviews
Self-selecting
sample, purposive
recruitment
strategies, self-
reports
***
Al-Falasi (2009)
[50]
UAE AAS users (34 male) and
non-AAS users (129 male &
female), age range not
specific
154 Quantitative: Self-administered
questionnaire
Self-report, small
sample size,
selective bias
**
Bojsen-Møller
(2010) [51]
Denmark General public (incl AAS
users), (not given for AAS
queries subset), 284 men,
40 women
374 Quantitative: Anti-Doping Hotline En-
quires: web and phone queries (sub-
set AAS use)
Self-selected,
missing data for
AAS users’ subset
**
Hope (2013) [52] England
& Wales
(UK)
Injectors of IPED (NSPs),
(n = 347 mean = 28 [not all
gave age]), men
395 Quantitative: unlinked-anonymous
cross-sectional biobehavioural survey
(oral fluid sample)
NSPs as settings ***
Hope (2013) [19] England
& Wales
(UK)
Injectors of IPED (NSPs),
(n = 319, mean: 28 [not all
gave age]), men
366 Quantitative: unlinked-anonymous
cross-sectional biobehavioural survey
(oral fluid sample)
same study as
above
***
van Beek (2015)
[53]
Australia Injectors of IPED (NSPs),
(mean = 32.6), men
103 Quantitative: Self-administered survey Recruited from 2
public healthcare
providers
***
Jacka (2017) [54] Australia Injectors of IPED, (median
27), men
100000 occasions Queensland NSP Minimum dataset NSPs as settings ***
Rowe (2017) [8] Australia Injectors of IPED, (mean =
28.8), men
605 Quantitative: Self-administered
questionnaire
NSPs as settings ***
Zahnow (2017)
[55]
Global AAS users, 253 men & 59
women (no exact No. after
exclusion criteria applied)
195 AAS users
with adverse
effects
Quantitative: Sub-section of global
drug survey – online
Self-nominating,
online only
**
Dennington (2008)
[34]
Australia IPED users, 61 men, 1
woman, 7 trans, 24, key
informants
69 (+ 24) #Mixed Methods: semi-structured inter-
views collecting quantitative and quali-
tative data
Report: not peer
reviewed. Data sets
not integrated
**
~ Quality Review: Davids and Roman’s [47] Quantitative Review Methodology. Appraisal Score: *** 67–100% & **34–66% score. #where practicable data analysed
from studies which included dealers or professional services providers, only findings from AAS users have been included
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adverse side-effects from credible sources [36] and some
AAS users acknowledged that not all information from
dealers was reliable [43]. Additionally, one study
highlighted self-experimentation as a key method for
working out the most efficacious doses [3].
Support for health issues
Some studies referenced IPED users ensuring that they
got their ‘bloods’ checked, and other tests done regularly
by a medical professional (Table 7) however, not all had
told their doctor about their IPED use [8, 19, 52, 58]. In
some countries, IPED users were able to access prescrip-
tion medicines [42, 59]. IPED users sought help from Ac-
cident and Emergency departments and NSPs and self-
medicated for AAS-related health issues [19] but it is un-
clear which, if any information sources they accessed on
how to self-treat. Help was sought from experienced users
[38] often through online fora [41]. All six AAS users in
Skårberg et al.’s study [38] were using an addiction clinic
to help manage their AAS use/dependency specifically to
support psychological problems. Differences were found
in the type of support or information sought dependent
on the type of participant and type of support offered.
Women were more likely to access health services than
men, and older men were more likely to access these than
younger men [55].
Ideal support
Figure 2 lists the kind of support that IPED users
wanted.
One study found that people who were thinking about
using AAS sought out detailed information to make in-
formed choices [36]. Requests were posted on internet
fora for information on side-effects and the most effective
ways to achieve results [44]. According to Dennington et
al. [33] users wanted to know the optimum way to use
IPED, where to acquire high quality substances, effective
nutrition and exercise regimes, safer injecting techniques,
Table 5 Data by type of information or support - Harm minimisation
Type of information / support Support sought from (if given) Article reference
Acquisition of injecting equipment Dealer(s) [36, 40, 43]
NSPs [19, 22, 39–41, 43, 51–54]
Chemist/Pharmacy [40, 41, 43, 52, 54]
Doctor(s) [39, 52, 54]
Friends(s)/Peer(s)/Social Network [41, 43, 52, 54]
Steroid Clinic(s) [22, 39]
Gym/Outreach services in Gyms [39, 54]
Online/Websites [40, 54]
Anti-Aging clinic(s) [41]
Outreach service/Other [22, 52]
Guidance on how to inject and safer
injection practices
Dealer(s)/Supplier(s) [8, 36, 40, 43]
Friend(s)/Peer(s)/Experienced Gym mate(s)/
Other AAS user(s)/Family
[8, 38–40, 46, 53]
Self-taught [52]
NSPs [51]
Online/Websites [8, 43]
Leaflets/Other sources [8, 43]
Personal trainer(s) [8]
Doctor(s)/Nurse(s) [8, 52, 55]
Blood Borne Virus screening~ Hep B and Hep C [8, 55]
Hep B (20%), Hep C (18%) [19]
Hep C (64%) [55]
Hep B (23%), Hep C (22%) [53]
HiV testing~ HiV [8, 55]
HiV (31%) [53]
HiV (64%) [54]
HiV (28%) [19]
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table. ~Percentage of participants where given
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safe ways to combine substances for effectiveness and
when to consult a doctor. Grogan et al. [37] reported that
women found much of the online information and ‘steroid
bibles’ male-centric and wanted more information on
side-effects for females.
In one study 66% of participants were willing to seek
medical supervision for their AAS use [58], and 91.6% of
users wished to use AAS legally under direct supervision
of a knowledgeable doctor [5]. Some AAS users were
frustrated by the limited health options available and
were willing to buy drugs from their doctor [41]. Users
expressed a desire for treatment for IPED-related phys-
ical problems, e.g. abscesses and the need for specific
services such as blood screening [33, 39]. Griffiths et al.
[42] found that AAS users wanted post-cycle therapy
(PCT) to stay healthy, minimise harms and to prevent
losing the gains acquired from use. Furthermore, a few
users suggested that IPED should be legal and medically
prescribed [33]. Some users wanted specialist IPED ser-
vices where drugs could be tested for purity and to know
how to avoid counterfeit drugs [33, 36]. The ideal sup-
port sought was focussed on managing health risks [5,
41]. Moreover, participants were also specific about how
that support should be delivered, wanting: 1. a place to
obtain credible advice and information that was non-
judgemental and balanced and 2. medical support by
knowledgeable professionals.
Discussion
In summary, it is clear a large number of AAS users seek
out information and support, predominantly from online
fora and from experienced AAS users. Professionals are
trying to tailor support to AAS users where resources
allow but few studies have explicitly asked users what
type of support they need. There is potentially a large
number of AAS users who have not been surveyed as
they are not accessing local substance use services or
choose not to complete surveys for fear of being classi-
fied as ‘junkies’ [60].
One key purpose of a review is to identify gaps in the
literature [61] and IPED users seemed to reject the
‘medical model’ that doctors are the experts as they give
credibility to advice from people who have used [33]
stating that doctors lacked credibility as they did not
Table 6 Data by type of information or support - Research and information seeking
Type of information / support Support sought from (if given) Article reference
Seeking of general information on IPED use: including
effectiveness, dosage, the effects, how to use, types of
substances/brand
Friend(s)/Experienced user(s)/Training
partners/Peers/Other user(s)/Family
[1, 2, 4, 8, 12, 13, 15, 16]
Online forums* [3, 8, 17]
Underground books/Magazines [1, 8, 13, 16, 18]
Doctor(s)/Medical practitioner(s)/Nurse(s) [1, 4, 12, 15]
Gym contact(s)/Gym trainer(s)/Personal trainers [1, 4, 12, 15, 19]
Dealer(s)/Supplier(s) [1–3, 11, 12, 15]
Questions to anti-doping hotline/Online service
on AAS
[20]
Internet/Specialist websites* [2–4, 12, 13, 15, 16, 18]
Medical journals [1]
NSP(s) [2, 4, 12, 15]
Steroid guides in gyms/Other sources [12, 15, 18]
Research into cycling, stacking and types of substances Peers/Fellow users [2, 13]
Websites [16]
Dealers [2]
Online forums [17]
Self-experimentation [16]
Research into side effects and risk management People with ‘hands-on’ experience of use/ Steroid
guides in gyms/ Underground books/Dedicated
websites
[18]
Questions to anti-doping hotline/Online service on
adverse side-effects/ Health risks
[20]
Doping tests Questions to anti-doping hotline/Online service on
obtaining positive doping test and penalties
[20]
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table. *It could be that when AAS users refer to websites
they might also mean specialist forums
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have personal experience [36]. This perspective is more
aligned to a social care perspective with the substance
user being the expert in their own use, hence the trust
in experienced users. One reason given for this lack of
credibility was that IPED users felt that the advice from
professionals was not balanced and focused on health
harms whilst ignoring the benefits [33]. Many argue for
professionals to be better informed [53, 55] so as to be
able to challenge the doses in ‘steroid bibles’ [37]. In a
society where men are affected by images of the idealised
male body image [62–64], and negative messages from
others, it is unsurprising that men adopt a range of strat-
egies to become more muscular [65–67]. Many of the
short-term effects of AAS use are reversible and not as
life-threatening as the long-term effects and the severity
of side-effects could be reduced with early access to
Table 7 Data by type of information or support – Support for health issues
Type of information/support Support sought from (if given) Article reference
Regular medical check-ups / Unspecified laboratory/Medical
tests including blood-tests
Not stated
Not stated but bloodwork obtained
[21]
[22]
Doctor(s)
Doctors (Liver function test, ECG, Diabetes tests)
[4] [12] [9]
[14]
Steroid Clinic (service provider information) [11]
Anti-aging clinics [9]
Consultation on specific AAS – related health issues Doctor
Doctor (includes discussion on mood)
Doctor (for PCT advice)
[21] [6] [5] [9]
[14]
[23]
Specialised addiction clinic (psychological problems) [13]
Sexual health clinics [5]
NSPs
NSPs (including < 1% interventions – drug treatment referrals)
[6] [5]
[7]
Accident & Emergency/walk-in [5] [6]
Anti-aging clinics [9]
Self-treatment and other [6]
Online websites/Forums [9]
Prescribed substances relating to AAS use Not stated [6]
Any data given about access of services that is not linked to AAS/IPED use has not been included in this table
Fig. 2 Ideal Support Wanted
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health services [55]. Consequently, having the appropri-
ate support in place for AAS users is vital and some rec-
ommend that peers could have a positive role in harm
minimisation [68].
The literature was sparse on the support that women
access and want; this was not unexpected as the majority
of AAS users are male [69]. Dennington et al’s. report
[33] was the only one to include transgender people.
This is a population that has not traditionally been iden-
tified within the research, but one small study found that
transgender youth had 26.6 times greater odds of AAS
use without a prescription than cisgender male respon-
dents [70]. It is worth considering that this group may
be using AAS as part of the transition from female to
male [71], but this is not necessarily the case and there-
fore more research on support for women and the trans-
gendering population would be useful, particularly
aligned to support needs.
Online information
Many users sought AAS information from the internet,
but the majority of online material presents a pro-use
position [72], can be incorrect or even dangerous [73]
and sites may sell steroids [74], which could put users at
risk and could perpetuate the impetus to use. Andreas-
son and Johansson [75] suggest that the online commu-
nity with its openness and acceptance of AAS use is part
of a culture of learning and education for novices. They
believe such communities can be seen to normalise AAS
use, the idea of obtaining an ‘ideal masculine body’ with-
out using AAS becoming a fantasy.
Support services
Most support from professionals has a harm minimisa-
tion focus. AAS users are already less likely than trad-
itional injecting substance users to engage in risky
injection practices [76] which could explain the low up-
take for BBV tests. However, AAS use does increase sex
drive [77] so this could increase sexual risk taking and
may explain why HIV tests uptake was higher than
BBVs. Users also sought help from sexual health clinics
[53]. If, however, IPED users do not perceive this as a
risk, they may not be engaging with services, and might
be accessing NSPs simply because the needles are free.
Three studies evidenced that guidance on injecting came
from AAS dealers [8, 40, 43]. This is concerning as
dealers often trivialised potential risks [37]. A good harm
minimisation strategy could be for gyms to provide a
safer injecting service [78] and this outreach service has
been provided in some UK gyms [39]. However, gyms
are often reluctant to provide anything that would
suggest that their clientele may be using AAS [79]. For
people who wish to access PCT there are few services
available. Hence the need to reconsider PCT support
due to the perceived needs linked to mental and physical
health [42].
Only two studies [38, 55] showed that AAS users seek
support for potential mood changes or underlying psycho-
logical issues. Kanayama et al. [69] concluded on the basis
of seven studies that 30% of illicit AAS users develop de-
pendence based on the Diagnostic and Statistical Manual
of Mental Disorders (DSM) IV criteria and therefore it is a
valid diagnostic entity. The DSM 5 [80] states that some
individuals with muscle dysmorphia (MD), a form of body
image disturbance, use AAS. Moreover, one study found
that men using AAS for image-related reasons reported
higher levels of MD and eating disorder symptomology
[79, 81] suggesting there is a need for more awareness
raising and that people showing such symptoms should be
supported through appropriate gender specific interven-
tions [82]. No study evidenced a need for support aligned
to stopping AAS use. Traditionally, UK substance misuse
support services offer talking treatments, and group and
one-to-one sessions for people dependent on substances,
yet there was no evidence in the UK studies of AAS users
accessing these services.
Previous studies have advocated that specialist steroid
services, created with input from AAS users are needed
[39]. There are comparatively few specialised support
services for people who use AAS and those few dedi-
cated Steroid Clinics, often publicly-funded harm reduc-
tion initiatives, are subject to the ‘whims’ of local
funding and resourcing. It would be useful to investigate
ways of engaging AAS users with health services [6]. A
useful strategy could be through health professionals en-
gaging with online fora as a mechanism for harm reduc-
tion providing the language used is that of the forum
and not of health professionals [44]. This would need to
include strategies to overcome the lack of trust AAS
users have in professionals. This review echoes these
recommendations and suggests that there is a case to
consider AAS users as a different population to trad-
itional substance users. The AAS users accessing NSPs
are more likely to be those who are injecting AAS and
not those who take AAS orally. People who only use oral
AAS are therefore potentially an even harder to reach
population who are nevertheless putting themselves at
risk. Dennington et al.’s [33] report examining current
users’ views on the information and support provision
found opposing views on types of support offered de-
pending on the individual perspective of the user. Recent
studies have identified distinct types of AAS user, each
with different motivations for use [59, 83]. Differing
motivations could be one reason why AAS users have
differing opinions on the support offered. Consequently,
offering information and support through a range of
services and mediums and targeted at the different types
of AAS use could be beneficial.
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Barriers to accessing support
This review did not explore why people may not access the
information and support that is currently available to them.
However, several studies highlighted reasons as to why AAS
users chose not to access specific services. When it came to
accessing NSPs, pharmacies, and doctors, AAS users spoke
of a fear of stigma or embarrassment [33, 39, 41, 43, 55],
and there were several other reasons given for not accessing
professional services [33, 36, 37, 41, 42, 55, 58]:
 perceived lack of trust or lack of knowledge from
professionals
 fear of judgemental reactions
 inability to obtain drugs wanted for PCT
 the need for private health insurance
 cost and difficulty of booking advance appointments
 not wanting to be identified as ‘drug’ users or as
visiting such support services
Generally, AAS users do not see themselves as “typ-
ical” drug users [33, 43]. Consequently, a key barrier for
accessing NSPs [33] was the presence of other types of
substance users. Another consideration could be the link
between AAS use and MD [84, 85] as research suggests
that people with MD may be in denial of this as a prob-
lem [86] and may not link it to their use of AAS. A lack
of recognition of an underlying psychological problem
would mean AAS users would not naturally seek any
type of psychological support.
Using AAS requires more preparation, research and
planning than other illicit drug use, and users take a
strategic approach looking to minimise harm and maxi-
mise results [58]. This could explain why AAS users jus-
tify their use as being different from other types of
people who use illicit substances. Whilst many felt a
stigma in attending NSPs, others felt these offered a dis-
creet service [41]. This area of barriers to accessing ser-
vices requires further investigation.
Weaknesses and strengths
As the search was limited to English language papers,
this could have excluded some studies. In studies where
participants were recruited from NSPs, the authors have
presumed that AAS users were accessing those services,
predominantly to obtain injecting equipment. Another
limitation is that data came from different countries,
which influences information and support available and
willingness to take part in surveys, e.g. AAS use in
Australia and America is illegal, whereas in the UK, it is
legal for personal use, but it is illegal to supply. A further
challenge has been to identify the types of substances
used within the literature and exactly what information
and support is related to which substance. However, as it
is likely that people who use AAS are also using these in
combination with a number of other substances to either
achieve their aims or mitigate side effects, it is plausible
that the support and information they seek is similar. To
our knowledge, this is the first scoping review on the
types of support accessed, and support wanted.
Conclusion
AAS users access a wide range of sources to obtain in-
formation on: injecting, effectiveness of substances, dos-
ages to use, side effects, cycling and stacking, and risk
management, which suggests that this is the type of in-
formation users want. AAS users seek out support from
medical professionals and NSPs for health issues, blood
tests, prescription substances, and equipment, suggesting
these types of support are wanted by AAS users. How-
ever, AAS users do not state or potentially recognise a
need for psychological support, or support to stop using.
Consideration of the barriers faced by users for accessing
services identified a need for services to take a non-
judgemental approach and have credible knowledge
around use. There is a need for AAS support to be spe-
cific and targeted, with further research required to
understand their experiences around drug-use and their
support needs. More research into the experiences of fe-
male and transgender AAS users and the stigma all AAS
users experience would be beneficial to ensure a less
‘one size fits all’ service provision. Providers of services
need to have an in-depth knowledge of benefits, harms
and range of drugs available and benefits of PCT. This
review echoes previous studies regarding the need to
gain a deeper understanding of methods that would en-
courage AAS users to seek support.
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